AstraZeneca has paused a £200m expansion of its Cambridge research site, stalling its entire £650m UK investment plan.
The project was expected to create 1,000 jobs, but joins the scrapped £450m vaccine facility in Merseyside.
The company confirmed the decision, citing regular reassessment of investment needs, but declined to comment further.
In contrast, AstraZeneca pledged \$50bn in US investments by 2030, including facilities in Virginia, Maryland, and Texas.
The pause adds to a week of setbacks for UK pharma, with Merck canceling a £1bn London research centre and cutting jobs.
Sir John Bell warned major pharmaceutical companies are turning away from the UK due to investment concerns.
Sanofi echoed the criticism, urging the Treasury to create a competitive life sciences plan before resuming investment.
Eli Lilly also froze its £279m London lab project, deepening fears for the UK’s ambition to be a science superpower.
Industry groups demand NHS pricing reforms, pressing for a reduced clawback rate to align with European standards.
AstraZeneca Halts £200m Cambridge Expansion Amid UK Pharma Turmoil
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment
Craze News delivers powerful stories, breaking news, sports, and culture—bringing bold perspectives and timely updates to keep readers informed, inspired, and connected worldwide.
We’re social. Connect with us:
© 2025 Craze News. All Rights Reserved.